Publications by authors named "Jonathan Goldman"

Claim this Profile
D
Durvalumab Plus Platinum-Etoposide in Extensive-Stage Small-Cell Lung Cancer: Outcomes in Age, Sex, and Platinum Subgroups From the Phase 3 CASPIAN Study.
Niels Reinmuth, Jonathan W Goldman, Yuanbin Chen, Katsuyuki Hotta, Dmytro Trukhin

Clin Lung Cancer· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Updated Overall Survival Analysis From the Phase II PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer.
Melissa L Johnson, Egbert F Smit, Enriqueta Felip, Suresh S Ramalingam, Myung-Ju Ahn, Jonathan W Goldman

J Clin Oncol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Stereotactic Body Radiation Therapy Utilization Trends for Stage I Non-Small Cell Lung Cancer.
Sara Sakowitz, Haley I Tupper, Lawrence N Benjamin, Scott Oh, Tao He, Jonathan Goldman

Chest· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC-A Brief Report.
Gregory J Riely, Myung-Ju Ahn, Jeffrey M Clarke, Ibiayi Dagogo-Jack, Raymond Esper, Jonathan W Goldman

J Thorac Oncol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
TNG260 Is a Small-Molecule CoREST Inhibitor That Sensitizes STK11-Mutant Tumors to Anti-PD-1 Immunotherapy.
Leanne G Ahronian, Soumyadip Sahu, Minjie Zhang, Ayushi S Patel, Ke Geng, Jonathan W Goldman

Cancer Res· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Osimertinib Plus Savolitinib in Patients With EGFR-Mutated Advanced NSCLC With MET Alterations After First-Line Osimertinib: Clinical Outcomes, Safety, and Biomarker Analysis: A Brief Report.
Xiuning Le, Christina Baik, Byoung Chul Cho, Jonathan W Riess, Zofia Piotrowska, Jonathan W Goldman

J Thorac Oncol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Amivantamab in Participants With Advanced NSCLC and MET Exon 14 Skipping Mutations: Final Results From the CHRYSALIS Study.
Matthew G Krebs, Byoung Chul Cho, Sandrine Hiret, Ji-Youn Han, Ki Hyeong Lee, Jonathan W Goldman

J Thorac Oncol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Poziotinib for EGFR exon 20-insertion NSCLC: Clinical efficacy of the phase 2 ZENITH trial and differential impact of EGFR exon 20 insertion location on sensitivity.
Xiuning Le, Jacqulyne P Robichaux, Monique Nilsson, R S K Vijayan, Ashwin Ravichandran, Jonathan W Goldman

Nat Commun· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-in-Human Phase I/IIa Study of the First-in-Class CDK2/4/6 Inhibitor PF-06873600 Alone or with Endocrine Therapy in Patients with Breast Cancer.
Timothy A Yap, Jonathan W Goldman, Shaveta Vinayak, Antoaneta Tomova, Erika Hamilton

Clin Cancer Res· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Brief Report: The Genomic Landscape of Small Cell Lung Cancer in Never-Smoking Patients.
Michael S Oh, Edward B Garon, Aaron E Lisberg, Amy L Cummings, Alex Barrett, Jonathan W Goldman

Clin Lung Cancer· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molecular residual disease analysis of adjuvant osimertinib in resected EGFR-mutated stage IB-IIIA non-small-cell lung cancer.
Roy S Herbst, Thomas John, Christian Grohé, Jonathan W Goldman, Terufumi Kato

Nat Med· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
ORCHARD: Osimertinib Plus Necitumumab in Patients With Epidermal Growth Factor Receptor-Mutated Advanced Non-Small Cell Lung Cancer With a Secondary Epidermal Growth Factor Receptor Alteration Whose Disease Had Progressed on First-Line Osimertinib.
Jonathan W Riess, Adrianus J de Langen, Santiago Ponce, Sarah B Goldberg, Zofia Piotrowska, Jonathan W Goldman

JCO Precis Oncol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neratinib Efficacy in Patients With EGFR Exon 18-Mutant Non-Small-Cell Lung Cancer: Findings From the SUMMIT Basket Trial.
Jonathan W Goldman, Alejandro Martinez Bueno, Christophe Dooms, Komal Jhaveri, Maria de Miguel

Clin Lung Cancer· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adverse events self-reported by patients with extensive-stage small-cell lung cancer in the phase III CASPIAN study.
Mustafa Özgüroğlu, Jonathan W Goldman, Yuanbin Chen, Marina Chiara Garassino, Nenad Medic

Future Oncol· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A plain language summary of results from the FLAURA2 study: Initial (first-line) osimertinib treatment with or without chemotherapy in patients with untreated EGFR-mutated advanced NSCLC.
David Planchard, Pasi A Jänne, Ying Cheng, James Chih-Hsin Yang, Noriko Yanagitani, Jonathan Goldman

Future Oncol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Author Correction: CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors.
Ferdinandos Skoulidis, Haniel A Araujo, Minh Truong Do, Yu Qian, Xin Sun, Jonathan W Goldman

Nature· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
Water Disinfection Systems for Pools and Spas: Advantages, Disadvantages, and Consumer Views in the US.
Mourin Jarin, Jackie Ly, Jonathan Goldman, Xing Xie

ACS ES T Water· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multiorgan transplant for therapy-associated lung and liver failure in a patient with stage III lung cancer.
Anitha Chandrasekhar, Hee Chul Yang, Tarik Demir, Anjana Yeldandi, Chitaru Kurihara, Jonathan W Goldman

Am J Transplant· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Current Trial Report: A Multicenter Phase I/Ib study of Capmatinib Plus Trametinib in Patients With Metastatic Nonsmall Cell Lung Center Harboring MET Exon 14 Skipping Mutations and Other MET-Alterations.
Matthew S Lara, Jonathan W Riess, Jonathan W Goldman, Fei Jiang, Trever G Bivona

Clin Lung Cancer· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors.
Ferdinandos Skoulidis, Haniel A Araujo, Minh Truong Do, Yu Qian, Xin Sun, Jonathan W Goldman

Nature· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein-Overexpressing Advanced Nonsquamous -Wildtype Non-Small Cell Lung Cancer in the Phase II LUMINOSITY Trial.
D Ross Camidge, Jair Bar, Hidehito Horinouchi, Jonathan Goldman, Fedor Moiseenko

J Clin Oncol· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sleep Disturbance as a Mediator of Lung Cancer Stigma on Psychological Distress and Physical Symptom Burden.
Timothy J Williamson, Edward B Garon, Michael R Irwin, Alyssa K Choi, Jonathan W Goldman

Psychosom Med· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molecular classification and biomarkers of outcome with immunotherapy in extensive-stage small-cell lung cancer: analyses of the CASPIAN phase 3 study.
Mingchao Xie, Miljenka Vuko, Jaime Rodriguez-Canales, Johannes Zimmermann, Markus Schick, Jonathan W Goldman

Mol Cancer· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A shared neoantigen vaccine combined with immune checkpoint blockade for advanced metastatic solid tumors: phase 1 trial interim results.
Amy R Rappaport, Chrisann Kyi, Monica Lane, Meghan G Hart, Melissa L Johnson, Jonathan W Goldman

Nat Med· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Summary of Research: Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC.
Masahiro Tsuboi, Roy S Herbst, Thomas John, Terufumi Kato, Margarita Majem, Jonathan W Goldman

Target Oncol· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis